Sborov D - Search Results

1

Financial toxicity in hematological malignancies: a systematic review.

Ouchveridze E, Banerjee R, Desai A, Aziz M, Lee-Smith W, Mian H, Berger K, McClune B, Sborov D, Qazilbash M, Kumar S, Mohyuddin GR. Ouchveridze E, et al. Among authors: sborov d. Blood Cancer J. 2022 Apr 22;12(4):74. doi: 10.1038/s41408-022-00671-z. Blood Cancer J. 2022. PMID: 35459862 Free PMC article.

2

Correction: HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide.

Canella A, Nieves HC, Sborov DW, Cascione L, Radomska HS, Smith E, Stiff A, Consiglio J, Caserta E, Rizzotto L, Zanesi N, Stefano V, Kaur B, Mo X, Byrd JC, Efebera YA, Hofmeister CC, Pichiorri F. Canella A, et al. Oncotarget. 2023 Sep 25;14:837-838. doi: 10.18632/oncotarget.28515. Oncotarget. 2023. PMID: 37747363 Free PMC article. No abstract available.

3

Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients.

Mohyuddin GR, Rooney A, Balmaceda N, Aziz M, Sborov DW, McClune B, Kumar SK. Mohyuddin GR, et al. Blood Adv. 2021 Feb 23;5(4):1097-1101. doi: 10.1182/bloodadvances.2020004017. Blood Adv. 2021. PMID: 33606005 Free PMC article. No abstract available.

4

The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance.

Castillo JJ, Callander NS, Baljevic M, Sborov DW, Kumar S. Castillo JJ, et al. Am J Hematol. 2021 Jul 1;96(7):846-853. doi: 10.1002/ajh.26155. Epub 2021 Mar 25. Am J Hematol. 2021. PMID: 33709474 Free PMC article. Review.

5

Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review.

Mohyuddin GR, Koehn K, Sborov D, McClune B, Abdallah AO, Goodman AM, Prasad V. Mohyuddin GR, et al. Among authors: sborov d. Lancet Haematol. 2021 Apr;8(4):e299-e304. doi: 10.1016/S2352-3026(21)00024-7. Lancet Haematol. 2021. PMID: 33770485

6

Hospitalization at the end of life in patients with multiple myeloma.

Abbasi S, Roller J, Abdallah AO, Shune L, McClune B, Sborov D, Mohyuddin GR. Abbasi S, et al. Among authors: sborov d. BMC Cancer. 2021 Mar 31;21(1):339. doi: 10.1186/s12885-021-08079-x. BMC Cancer. 2021. PMID: 33789626 Free PMC article.

7

Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: A systematic review and meta-analysis.

Mohyuddin GR, Atieh T, Ahmed N, Sborov D, McClune B, Abdallah AO, Goodman AM, Aziz M, Allen I, Prasad V. Mohyuddin GR, et al. Among authors: sborov d. Eur J Cancer. 2021 Oct;156:164-174. doi: 10.1016/j.ejca.2021.07.036. Epub 2021 Aug 26. Eur J Cancer. 2021. PMID: 34454318

8

Optimizing Thromboembolism Prophylaxis for the Contemporary Age of Multiple Myeloma.

Baljevic M, Sborov DW, Lim MY, Hillengass J, Martin T, Castillo JJ, Streiff MB, Kumar SK, Callander NS. Baljevic M, et al. J Natl Compr Canc Netw. 2022 Jan;20(1):91-95. doi: 10.6004/jnccn.2021.7112. J Natl Compr Canc Netw. 2022. PMID: 34991076 Review.

9

Heterogeneity of enrolment criteria for ongoing smouldering myeloma trials.

Soomro MA, Hoffman J, Goodman AM, Sborov DW, Mohyuddin GR. Soomro MA, et al. Br J Haematol. 2022 Jun;197(6):e86-e88. doi: 10.1111/bjh.18102. Epub 2022 Feb 28. Br J Haematol. 2022. PMID: 35229286 No abstract available.

10

Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic review.

Wesson W, Galate VL, Sborov DW, McClune B, Goodman AM, Gyawali B, Prasad V, Abbasi S, Mohyuddin GR. Wesson W, et al. Eur J Cancer. 2022 May;167:152-160. doi: 10.1016/j.ejca.2021.12.037. Epub 2022 Feb 27. Eur J Cancer. 2022. PMID: 35236569

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

91 results

Search Page